Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
130
resultados
Última actualización
10/03/2025 [07:23:00]
Resultados 50 a 75 de 130
Resumen de: US2025049740A1
The present disclosure relates to a compound and the use thereof in the preparation of a medicament for treating Alzheimer's disease. The present disclosure provides a method for constructing an animal model of diseases with N-oleoyl-dopamine (OLDA) and the use of the model in drug screening and animal experimental research, wherein the animal model includes at least one of an animal model of neurodegenerative diseases, an animal model of intestinal permeability diseases, and an animal model of inflammatory diseases. The present disclosure is based on the discovery that OLDA has a new use for a neurodegenerative disease, an intestinal permeability disease, and an inflammatory disease, and based on OLDA, compounds that have a therapeutic effect on the above diseases are identified.
Resumen de: WO2025030709A1
Disclosed in the present invention is a β-carboline compound having a structure as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is halogen; X is O or NH; n is 1 or 2; ring A is 3- to 6-membered cycloalkyl, 4- to 6-membered heterocyclyl, aryl or heteroaryl; and R2 is H, halogen, cyano, nitro, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl. The compound or the salt thereof of the present invention has a relatively high selective inhibitory effect on MAO-B, has a significantly higher in-vitro MAO-B inhibitory activity and selectivity than safinamide, and has a reversible inhibitory effect on MAO-B. The compound or the salt thereof of the present invention can be used for treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Further disclosed in the present invention is the use of the β-carboline compound or the pharmaceutically acceptable salt thereof in the preparation of an MAO-B inhibitor or in the preparation of a drug for treating and/or preventing diseases regulated by a monoamine oxidase B inhibitor.
Resumen de: AU2023319981A1
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will respond to LRRK2 inhibitors. Thus, the invention provides methods of identifying PD patients who will respond to LRRK2 inhibitors and methods of treating such patients.
Resumen de: WO2025030991A1
The present application relates to Bifidobacterium longum subsp. infantis capable of relieving Parkinson's disease and the use thereof. Said strain is named as Bifidobacterium longum subsp. infantis BI03 strain, with an accession number of CGMCC No. 24473, the preservation date thereof being March 07, 2022. Said strain can significantly relieve the symptoms of Parkinson's disease, specifically embodied in: relieving Parkinson's disease related dyskinesia and increased corticosterone levels; alleviating neuroinflammation related to Parkinson's disease; promoting glutathione and reducing brain oxidative stress injuries, etc.
Resumen de: US2025049741A1
The present invention relates to a composition for preventing or treating Alzheimer's disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer's disease.
Resumen de: US2025051766A1
Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).
Resumen de: US2025051750A1
Provided are an aromatic L-amino acid decarboxylase (AADC)/glial cell line-derived neurotrophic factor (GDNF) polynucleotide, and a use thereof in treating Parkinson's disease. Specifically, provided are a method for and a use in treating neurodegenerative diseases (such as Parkinson's disease) by delivering AADC and a GDNF to specific areas of the brain by a gene delivery system using AAV as a vector.
Resumen de: US2025051345A1
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
Resumen de: US2025051427A1
Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-Aβ protofibril antibody and anti-tau antibody.
Resumen de: US2025051264A1
Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The cannabidiol derivative is obtained by screening from a series of synthetic derivatives. An animal testing result shows that the cannabidiol derivative can reduce the balance beam score of a Parkinson's model animal and improve the dopamine level and the tyrosine hydroxylase (TH) cell positive rate in substantia nigra (SubN), can be used for drug development and research of various diseases such as epilepsy and Parkinson's disease, and has better application value.
Resumen de: EP4506012A1
The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Resumen de: EP4506013A1
The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Resumen de: AU2023241739A1
The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease.
Resumen de: EP4506011A1
This application provides compositions for the treatment of intractable neurological diseases and methods for their production, enabling the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The composition for treating intractable neurological diseases is characterized in that it contains culture supernatant obtained by culturing deciduous dental pulp stem cells in serum-free medium under ultrasound irradiation. A pharmaceutical product for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, characterized in that it contains the composition for the treatment of intractable neurological diseases. A method for producing a composition for treating intractable neurological diseases, characterized in that the composition contains a culture supernatant obtained by culturing deciduous dental pulp stem cells under ultrasound irradiation using serum-free medium. The method of manufacturing the composition for the treatment of intractable neurological diseases.
Resumen de: AU2023249247A1
Methods to alleviate or treat Alzheimer's Disease or a neurological disorder or disorder, or to alleviate the symptoms of each thereof are provided, the methods comprising administering an effective amount of (HSPC) or a population of HSPCs to the subject, that are optionally gene-corrected prior to administration and that will differentiate on healthy microglia cells in the brain. The cells are capable of decreasing amyloid plaques and inflammation.
Resumen de: KR20250020867A
본 발명은 ML324를 유효성분으로 포함하는 알츠하이머 치매 예방 또는 치료용 조성물에 관한 것으로, 본 발명의 ML324는 인지 기능 손상을 차단하고 Aβ 침전물을 감소시키며, 나아가 뇌 염증을 효과적으로 감소시키므로, 이를 포함하는 약학적 조성물은 산업에 유용하게 활용될 수 있다.
Resumen de: US2025041317A1
Provided herein are methods for improving working memory and/or executive function in a subject suffering from Huntington's Disease, comprising administering to the subject SAGE-718, an investigational positive allosteric modulator of the NMDA receptor.
Resumen de: US2025041248A1
Provided herein are methods for treating Alzheimer's disease using increased dosages amounts of ALZ-801.
Resumen de: US2025042865A1
ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(−)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.
Resumen de: US2025041247A1
The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-AUG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Exemplary diseases associated with repeat expansions include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, myotonic dystrophy type 1, myotonic dystrophy type 2, spinocerebellar ataxia, Alzheimer's disease, Huntington's disease, Fragile X Tremor Ataxia Syndrome, and Fragile XE syndrome.
Resumen de: US2025042979A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
Resumen de: US2025042873A1
Compounds and methods for treating proteotoxicity-associate diseases, including neurodegenerative diseases, such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), are disclosed.
Resumen de: WO2025030155A1
Among other things, the present disclosure provides various technologies including chirally controlled oligonucleotide compositions and technologies tor manufacturing and using such oligonucleotide compositions. In some embodiments, the present disclosure provides technologies useful for allele -specific knockdown of mutant Huntingtin transcripts. In some embodiments, tire present disclosure provides technologies useful for reducing the expression, level, amount, and/or activity of mutant Huntingtin transcripts or products thereof. In some embodiments, the present disclosure provides methods for treating Huntington's disease.
Resumen de: AU2023240256A1
Aspects of the disclosure relate to compositions and methods useful for treating Parkinson's disease. In some embodiments, the disclosure provides a method for treating Parkinson's disease comprising administration of a viral vector comprising a GDNF nucleic acid sequence. In some embodiments, administration is locally to the subject putamen. In some embodiments, administration is systemically, e.g., via the viral vector comprising a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.
Nº publicación: EP4499225A1 05/02/2025
Solicitante:
COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER REGN OF SOC A [IN]
NAT INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES NIMHANS [IN]
Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860),
National Institute of Mental Health and Neurosciences (NIMHANS)
Resumen de: WO2023187838A1
Phialomustin B (1) for treatment of Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS) The present invention provides Phialomustin B (1) a natural product isolated from the endophytic fungus Phialophora Mustea from the Corms of Crocus sativus. The present invention describes therapeutic potential of Phialomustin B (1) as Keap1 inhibitor for Parkinson's disease (PD) and SOD-1 modulator for Amyotrophic lateral sclerosis (ALS). The present invention also provides a pharmaceutical composition comprising an effective amount of Phialomustin B (1) of Formula I.
BOPI
Sede Electrónica
